X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
0.338
-0.030 (-8.25%)
At close: Nov 22, 2024, 4:00 PM
0.347
+0.009 (2.66%)
After-hours: Nov 22, 2024, 7:36 PM EST
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 93 employees as of December 31, 2023. The number of employees increased by 23 or 32.86% compared to the previous year.
Employees
93
Change (1Y)
23
Growth (1Y)
32.86%
Revenue / Employee
$12,075
Profits / Employee
-$180,204
Market Cap
57.64M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 93 | 23 | 32.86% |
Dec 31, 2022 | 70 | -13 | -15.66% |
Dec 31, 2021 | 83 | 11 | 15.28% |
Dec 31, 2020 | 72 | 14 | 24.14% |
Dec 31, 2019 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Xtant Medical Holdings | 215 |
Champions Oncology | 210 |
Celularity | 120 |
Mural Oncology | 117 |
Precision BioSciences | 109 |
Owlet | 76 |
Boundless Bio | 72 |
Modular Medical | 40 |
XFOR News
- 8 days ago - X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - GlobeNewsWire
- 21 days ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences - GlobeNewsWire